XL413 is primarily used in research settings as a potent and selective inhibitor of Cdc7 kinase, an enzyme involved in DNA replication and cell cycle regulation. Its application is focused on studying the mechanisms of cell proliferation and the potential therapeutic effects in cancer treatment. By inhibiting Cdc7, XL413 can halt the replication of cancer cells, making it a valuable tool for understanding tumor growth and developing targeted therapies. Additionally, it is utilized in preclinical studies to explore its efficacy in combination with other anticancer agents, aiming to enhance treatment outcomes. Its role in research underscores its importance in advancing cancer biology and drug development.